Compare H2O America (HTO) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs Merck & Co., Inc. — how do they compare? H2O America trades at $62.3 (market cap $2.61B), while Merck & Co., Inc. trades at $133.12 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 123.3× H2O America's market cap, and H2O America pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| HTO | MRK | |
|---|---|---|
Market Cap | $2.61B | $321.77B |
Sector | Technology | Health |
52-Week High | $65.43 | $131.84 |
52-Week Low | $44.44 | $77.60 |
Enterprise Value | $4.40B | $368.53B |
Dividend Yield | 2.83% | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $62.57, up 2.16% with bullish technical signals and strong analyst support. The stock shows solid fundamentals with 12.91% net margin and consistent earnings beats in recent quarters. Recent transformative acquisitions in Texas water utilities drive growth potential, though execution risks and share dilution from equity issuance present challenges. Technical indicators show bullish momentum with key resistance at $63 and support at $61.
Outlook remains positive with 83% analyst buy ratings and $69.50 consensus target offering 11% upside. Dividend sustainability and acquisition integration are key watchpoints. Risks include execution challenges from Quadvest deal and potential EPS dilution from recent 11M share issuance.
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
